Cordis US Corp.
$1.5M 2,469 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
VectivBio AG
VectivBio AG reported $1,511,032.42 across General Payments, Research, and Ownership to 10 physicians and teaching hospitals across 156 transactions.
- $1.5M Above-median payer
- All-tracks total
- 156 Below-median volume
- Transactions
- 10 Below-median reach
- Recipients
- +$26.2K
- General Payments vs PY2023
VectivBio AG reported $1,511,032.42 across all CMS Open Payments tracks (General + Research + Ownership) to 10 physicians and teaching hospitals in Program Year 2024 - ranking #523 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $30,066.23, averaging $151.1K per recipient.
How VectivBio AG's $1.5M all-tracks total breaks down
VectivBio AG's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
24/100
Transaction volume
F
11/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer vectivbio-ag VectivBio AG
$1.5M · #523/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #523
- SHARE 0.0%
- TXN 156
- RCP 10
- CAT 2
- GEN $30.1K
- ΔGEN +$26.2K
- TOP1 27.4%
- PY 2024
Volume peers
Nearest volume peer: Cordis US Corp. ($1.5M)
VectivBio AG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
VectivBio AG's CMS-reported General Payments increased by $26.2K (+686.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: VECTIVBIO AGPY2024: VectivBio AG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $3,822.72
- PY2024
- $30,066.23
What the Data Shows for VectivBio AG
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For VectivBio AG, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $29.0K across 9 transactions, 96.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, VectivBio AG's largest category was "Consulting Fee" at $29.0K - 96.3% of General Payments.
How VectivBio AG divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $29.0K | 9 | 96.3% |
| Travel and Lodging | $1.1K | 1 | 3.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $28,738.73 (95.6%) of $30,066.23 in this company's General Payments records across 7 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for VectivBio AG
The five named recipients with the highest reported General Payments from this company
- 1
Yi Bin Chen
$8,250.00 across 1 reported transactions
- 2
Andrew Mulberg
$6,000.00 across 3 reported transactions
- 3
John Levine
$5,750.00 across 1 reported transactions
- 4
Kishore Iyer
$5,363.73 across 2 reported transactions
- 5
Robert Venick
$3,375.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
VectivBio AG's spend rank (#523 of 1,925, top 27% by spend) and concentration rank (#758 of 1,838, top 41% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Diality Inc. : $1.5K total payments, HHI 2011
- FUJIFILM Corporation : $77.8K total payments, HHI 2008
- Radformation Inc : $1.7K total payments, HHI 2007
- Endolumik, Inc. : $7.8K total payments, HHI 2005
- Ecs Opco 1 LLC : $1.6K total payments, HHI 1973
- OrthoFundamentals, LLC : $57.3K total payments, HHI 1972
- VectivBio AG (this company) : $30.1K total payments, HHI 1971
- Trice Medical, Inc. : $369.8K total payments, HHI 1959
- Dentsply Ih Ab : $186.8K total payments, HHI 1956
- G21 Srl : $9.2K total payments, HHI 1918
- R-Pharm US LLC : $588.45 total payments, HHI 1917
- Dmg America LLC : $176.1K total payments, HHI 1902
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as VectivBio AG's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about VectivBio AG.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with VectivBio AG.
Showing 6 of 1,924 companies with CMS-reported payment data.
Vital Connect, Inc
$1.5M 832 recipients
Compare payment profiles
Fresenius Kabi USA, LLC
$1.5M 8,126 recipients
Compare payment profiles
ExThera Medical Corporation
$1.5M 15 recipients
Compare payment profiles
Artivion, Inc.
$1.5M 1,638 recipients
Compare payment profiles
Invivyd Inc
$1.5M 268 recipients
Compare payment profiles
Put this to use
VectivBio AG ranks #523 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where VectivBio AG sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just VectivBio AG. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.